ClinicalTrials.gg
CompletedNCT05007106Updated Sep 28, 2026Results posted

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

A Phase 2 interventional study of Pembrolizumab/Vibostolimab Co-Formulation and Pembrolizumab in Uterine Cervical Neoplasms, Endometrial Neoplasms and Squamous Cell Carcinoma of Head and Neck, sponsored by Merck Sharp & Dohme LLC. Completed at 73 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know · 37 judgments

Updated Sep 28, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
611
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc — 3 open to participants now, 6 under way, 2 of them phase 3. Uterine Cervical Neoplasms · Merck & Co., Inc.

Enrollment
18th of 29
611 · median 680
Started
2021
the only one that year
Phase 2
7 of 31
none open now
Registered
26th of 31
by date

Among the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, this one is the 18th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 26th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

3 of the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

03

Conditions studied

  • Uterine Cervical Neoplasms
  • Endometrial Neoplasms
  • Squamous Cell Carcinoma of Head and Neck
  • Gallbladder Neoplasms
  • Cholangiocarcinoma
  • Esophageal Neoplasms
  • Triple Negative Breast Neoplasms
  • Hepatocellular Carcinoma
  • Urinary Bladder Neoplasms
  • Ovarian Neoplasms
  • Stomach Neoplasms

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • One of the following or cytologically confirmed, advanced (unresectable or ) solid tumors:

    • Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
    • Endometrial cancer
    • Head and neck squamous cell carcinoma (HNSCC)
    • Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
    • Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
    • Triple-negative breast cancer (TNBC)
    • Hepatocellular carcinoma (HCC)
    • Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra
    • Ovarian cancer
    • Gastric cancer
  • per v1.1 as assessed by BICR or local site investigator.
  • Adequately controlled blood pressure (BP) with or without antihypertensive medications.
  • (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).
  • Male participants must agree to follow guidance.
  • Female participants are not pregnant or breastfeeding, not a woman of (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • History of a second , unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
  • Prior therapy with anti-programmed cell-death (), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
  • Prior systemic anticancer therapy including agents within 4 weeks before randomization/allocation.
  • Received a live or within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
  • Diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days before the first dose of study medication.
  • Active disease that has required systemic treatment in past 2 years.
  • Active infection requiring systemic therapy.
  • Concurrent active and virus infection.
  • History of allogenic tissue/solid organ transplant.
  • Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
  • Has cardiovascular disease within 12 months from first dose of study intervention.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
611 participants (actual)

Study arms

  • Experimental
    Pembrolizumab/Vibostolimab Co-Formulation

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy.

    Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab

  • Experimental
    Pembrolizumab

    Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.

    Biological: Pembrolizumab

  • Experimental
    Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

    Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab · Drug: Lenvatinib

  • Experimental
    Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or lenvatinib 8 mg (BW \<60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

    Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab · Drug: Lenvatinib

  • Experimental
    Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin.

    Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab · Drug: 5-Fluorouracil · Drug: Cisplatin

  • Experimental
    Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel.

    Biological: Pembrolizumab/Vibostolimab Co-Formulation · Biological: Pembrolizumab · Drug: Paclitaxel

  • Experimental
    Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin

    Biological: Pembrolizumab · Drug: Cisplatin · Drug: Gemcitabine

  • Experimental
    Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab.

    Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin · Drug: Docetaxel · Drug: Bevacizumab

  • Experimental
    Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin

    Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin.

    Biological: Pembrolizumab · Drug: Capecitabine · Drug: Oxaliplatin

Interventions

  • BiologicalPembrolizumab/Vibostolimab Co-Formulation

    Drug page: Vibostolimab/Pembrolizumab MK-7684AStudies of Vibostolimab/Pembrolizumab MK-7684AVibostolimab/Pembrolizumab MK-7684A pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

    Also known as: MK-7684A

  • BiologicalPembrolizumab

    Pembrolizumab 200 mg administered via IV infusion Q3W.

    Also known as: MK-3475, KEYTRUDA®

  • Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

    Also known as: Lenvima, E7080, MK-7902

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

    Also known as: 5-FU, Fluracil

  • Cisplatin administered via IV infusion

    Also known as: Platinol, cis Platinum

  • Paclitaxel administered via IV infusion at investigator's choice of dose

    Also known as: Taxol, Abraxane, Anzatax

  • Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

  • Carboplatin administered via IV infusion at investigator's choice of dose and frequency

  • For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

  • Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

  • Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

  • Oxaliplatin administered via IV infusion Q3W up to 35 cycles

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1

    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen \& Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented.

    Time frame: Up to approximately 24 months

  2. Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented.

    Time frame: Up to approximately 24 months

  3. ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors

    ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented.

    Time frame: Up to approximately 24 months

  4. Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months

    PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

    Time frame: 9 months

  5. PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months

    PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

    Time frame: 12 months

Secondary outcomes

  1. Overall Survival (OS) in Participants With Selected Solid Tumors

    For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented.

    Time frame: Up to approximately 46 months

  2. PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors

    PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented.

    Time frame: Up to approximately 46 months

  3. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1

    For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1.

    Time frame: Up to approximately 46 months

  4. DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors

    For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented.

    Time frame: Up to approximately 46 months

  5. ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1

    ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented.

    Time frame: Up to approximately 24 months

  6. PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented.

    Time frame: Up to approximately 24 months

  7. Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented.

    Time frame: Baseline and up to Week 12

  8. Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented.

    Time frame: Baseline and up to Week 12

  9. Number of Participants Who Experienced One or More Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm.

    Time frame: Up to approximately 46 months

  10. Number of Participants Who Discontinued Study Intervention Due to an AE

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.

    Time frame: Up to approximately 46 months

07

Results

Posted Sep 28, 2026

Participant flow

Initially, participants were randomly assigned (Cohort A1) or nonrandomly allocated (Cohorts A2-G). At Amendment 05, 4 new cohorts (D2, H, I, J) were added.

Participant flow — Overall Study
MilestoneCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + Oxaliplatin
Started8584314141434110404241413041
Second course mk-7684a00000000200000
Switch to pembrolizumab00040011100556
Completed00000000000000
Not completed8584314141434110404241413041
Withdrew: Physician decision00001000000111
Withdrew: Lost to follow-up01010100002000
Withdrew: Death69622215263337627292621827
Withdrew: Sponsor's decision13167231393410910192011
Withdrew: Withdrawal by subject35221010343012

Outcome measures

PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen \& Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented.

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1
Percentage of ParticipantsCohort A1 MK-7684ACohort A1 Pembrolizumab
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A120.0 (12.1 to 30.1)15.5 (8.5 to 25.0)
Statistical analysis
  • Cohort A1 MK-7684A vs Cohort A1 Pembrolizumab · Miettinen & Nurminen method · p = 0.2215 (One-sided p-value for testing) · Difference in percentage: 4.5 · 95% CI -7.2 to 16.3Based on Miettinen \& Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS)
PrimaryProgression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented.

Time frame:
Up to approximately 24 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1
MonthsCohort A1 MK-7684ACohort A1 Pembrolizumab
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A12.2 (2.1 to 4.2)2.1 (2.1 to 2.3)
Statistical analysis
  • Cohort A1 MK-7684A vs Cohort A1 Pembrolizumab · Log Rank · p = 0.4787 (One-sided p-value based on log-rank test stratified by prior bevacizumab use (IVRS)) · Hazard ratio (hr): 0.99 · 95% CI 0.70 to 1.38Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior bevacizumab use IVRS.
PrimaryORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented.

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of Participants
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Percentage of ParticipantsCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + Oxaliplatin
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors——16.1 (5.5 to 33.7)65.0 (48.3 to 79.4)42.5 (27.0 to 59.1)28.6 (15.7 to 44.6)12.5 (4.2 to 26.8)20.0 (2.5 to 55.6)52.5 (36.1 to 68.5)28.6 (15.7 to 44.6)22.0 (10.6 to 37.6)29.3 (16.1 to 45.5)—39.0 (24.2 to 55.5)
PrimaryProgression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

Time frame:
9 months
Reported as:
Number · Percentage of Participants
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months
Percentage of ParticipantsCohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months64.1 (27.9 to 85.6)
PrimaryPFS Per RECIST 1.1 as Assessed by Investigator at 12 Months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

Time frame:
12 months
Reported as:
Number · Percentage of Participants
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months
Percentage of ParticipantsCohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months32.1 (7.7 to 60.4)
SecondaryOverall Survival (OS) in Participants With Selected Solid Tumors

For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented.

Time frame:
Up to approximately 46 months
Reported as:
Median · Months
Overall Survival (OS) in Participants With Selected Solid Tumors
MonthsCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + Oxaliplatin
Overall Survival (OS) in Participants With Selected Solid Tumors10.2 (7.2 to 15.2)10.3 (8.4 to 14.7)12.8 (7.9 to 24.0)NA (18.6 to NA)22.9 (11.6 to 32.2)15.7 (10.6 to 19.1)7.0 (3.7 to 11.1)20.0 (6.5 to NA)17.8 (12.3 to 21.7)13.1 (8.7 to 21.7)19.8 (13.5 to 22.4)16.9 (10.3 to NA)NA (10.0 to NA)12.3 (9.1 to 16.0)
SecondaryPFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors

PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented.

Time frame:
Up to approximately 46 months
Reported as:
Median · Months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
MonthsCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + Oxaliplatin
PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors——2.2 (2.0 to 4.2)15.0 (8.1 to NA)6.4 (4.8 to 8.3)4.1 (2.3 to 8.4)2.4 (2.1 to 4.3)12.8 (4.1 to 20.5)10.4 (6.4 to 18.0)4.3 (3.9 to 6.2)9.2 (6.2 to 12.4)4.7 (2.2 to 10.5)10.6 (5.9 to 13.3)8.3 (4.4 to 10.5)
SecondaryDuration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1.

Time frame:
Up to approximately 46 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1
MonthsCohort A1 MK-7684ACohort A1 Pembrolizumab
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A110.9 (5.3 to NA)NA (NA to NA)
SecondaryDOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented.

Time frame:
Up to approximately 46 months
Reported as:
Median · Months
DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
MonthsCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + Oxaliplatin
DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors——10.8 (9.6 to NA)21.8 (12.7 to NA)8.3 (4.4 to 29.8)12.7 (4.2 to NA)15.9 (5.5 to NA)15.6 (12.7 to NA)13.9 (7.9 to NA)10.5 (4.2 to NA)13.7 (6.0 to NA)13.1 (8.5 to NA)—9.7 (6.2 to NA)
SecondaryORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented.

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of Participants
ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1
Percentage of ParticipantsCohort A1 MK-7684ACohort A1 Pembrolizumab
ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A120.0 (12.1 to 30.1)16.7 (9.4 to 26.4)
Statistical analysis
  • Cohort A1 MK-7684A vs Cohort A1 Pembrolizumab · Miettinen & Nurminen method · Difference in percentage: 3.3 · 95% CI -8.6 to 15.3Based on Miettinen \& Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS)
SecondaryPFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented.

Time frame:
Up to approximately 24 months
Reported as:
Median · Months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1
MonthsCohort A1 MK-7684ACohort A1 Pembrolizumab
PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A12.2 (2.1 to 4.3)2.3 (2.1 to 4.0)
Statistical analysis
  • Cohort A1 MK-7684A vs Cohort A1 Pembrolizumab · Log Rank · Hazard ratio (hr): 0.98 · 95% CI 0.70 to 1.37Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by prior bevacizumab use IVRS.
SecondaryChange From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented.

Time frame:
Baseline and up to Week 12
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1
Score on a ScaleCohort A1 MK-7684ACohort A1 Pembrolizumab
Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A10.77 (-3.84 to 5.38)3.53 (-1.13 to 8.20)
Statistical analysis
  • Cohort A1 MK-7684A vs Cohort A1 Pembrolizumab · Constrained Longitudinal Data Analysis · p = 0.368 · Difference in ls means: -2.76 · 95% CI -8.81 to 3.29
SecondaryChange From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented.

Time frame:
Baseline and up to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1
Score on a scaleCohort A1 MK-7684ACohort A1 Pembrolizumab
Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1-3.58 (-8.29 to 1.14)-3.14 (-7.96 to 1.68)
Statistical analysis
  • Cohort A1 MK-7684A vs Cohort A1 Pembrolizumab · Constrained Longitudinal Data Analysis · p = 0.896 · Constrained longitudinal data analysis: -0.44 · 95% CI -7.07 to 6.19
SecondaryNumber of Participants Who Experienced One or More Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Adverse Events (AEs)
ParticipantsCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + Oxaliplatin
Number of Participants Who Experienced One or More Adverse Events (AEs)8378314040413910394141402840
SecondaryNumber of Participants Who Discontinued Study Intervention Due to an AE

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.

Time frame:
Up to approximately 46 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to an AE
ParticipantsCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + Oxaliplatin
Number of Participants Who Discontinued Study Intervention Due to an AE143317181243141211111226

Adverse events

Collected over Up to approximately 46 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A1 MK-7684A71/85 (83.5%)43/85 (50.6%)79/85 (92.9%)
Cohort A1 Pembrolizumab66/84 (78.6%)33/83 (39.8%)74/83 (89.2%)
Cohort A2 MK-7684A23/31 (74.2%)16/31 (51.6%)31/31 (100%)
Cohort B1 MK-7684A15/41 (36.6%)23/40 (57.5%)40/40 (100%)
Cohort B1 Switch to Pembrolizumab0/4 (0%)0/4 (0%)3/4 (75%)
Cohort B2 MK-7684A + Lenvatinib 20 mg26/41 (63.4%)27/40 (67.5%)40/40 (100%)
Cohort C MK-7684A34/43 (79.1%)16/42 (38.1%)39/42 (92.9%)
Cohort D1 MK-7684A37/41 (90.2%)21/40 (52.5%)37/40 (92.5%)
Cohort D1 Switch to Pembrolizumab0/1 (0%)0/1 (0%)0/1 (0%)
Cohort D2 MK-7684A + Gemcitabine + Cisplatin6/10 (60%)5/10 (50%)10/10 (100%)
Cohort D2 Switch to Pembrolizumab + Gemcitabine + Cisplatin0/1 (0%)0/1 (0%)1/1 (100%)
Cohort E MK-7684A + 5-FU + Cisplatin26/40 (65%)23/40 (57.5%)39/40 (97.5%)
Cohort E to 2nd Course MK-7684A + 5-FU + Cisplatin1/2 (50%)1/2 (50%)0/2 (0%)
Cohort E Switch to Pembrolizumab + 5-FU + Cisplatin0/1 (0%)0/1 (0%)1/1 (100%)
Cohort F MK-7684A + Paclitaxel31/42 (73.8%)18/42 (42.9%)40/42 (95.2%)
Cohort G MK-7684A + Lenvatinib 12 mg/ 8 mg28/41 (68.3%)28/41 (68.3%)41/41 (100%)
Cohort H MK-7684A21/41 (51.2%)17/41 (41.5%)39/41 (95.1%)
Cohort H Switch to Pembrolizumab0/5 (0%)0/5 (0%)4/5 (80%)
Cohort I MK-7684A + Carboplatin + Paclitaxel + Bevacizumab8/30 (26.7%)12/28 (42.9%)28/28 (100%)
Cohort I Switch to Pembrolizumab + Carboplatin + Paclitaxel + Bevacizumab0/5 (0%)0/5 (0%)4/5 (80%)
Cohort J MK-7684A + Capecitabine + Oxaliplatin27/41 (65.9%)28/41 (68.3%)38/41 (92.7%)
Cohort J Switch to Pembrolizumab + Capecitabine + Oxaliplatin2/6 (33.3%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 246
Most frequent serious events
EventCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B1 Switch to PembrolizumabCohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D1 Switch to PembrolizumabCohort D2 MK-7684A + Gemcitabine + CisplatinCohort D2 Switch to Pembrolizumab + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort E to 2nd Course MK-7684A + 5-FU + CisplatinCohort E Switch to Pembrolizumab + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort H Switch to PembrolizumabCohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort I Switch to Pembrolizumab + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + OxaliplatinCohort J Switch to Pembrolizumab + Capecitabine + Oxaliplatin
Renal failureRenal and urinary disorders1/850/831/311/400/40/400/420/400/10/100/10/401/20/10/420/410/410/50/280/50/410/6
DysphagiaGastrointestinal disorders0/850/830/310/400/40/401/420/400/10/100/11/400/20/10/420/410/410/50/280/50/411/6
VomitingGastrointestinal disorders0/850/830/310/400/41/400/420/400/10/100/10/400/20/10/420/410/410/51/280/51/411/6
Septic shockInfections and infestations3/850/831/310/400/41/400/420/400/10/100/10/400/20/11/420/410/410/50/280/50/411/6
Febrile neutropeniaBlood and lymphatic system disorders0/850/830/310/400/40/400/420/400/10/100/10/400/20/10/420/410/410/53/280/51/410/6
Urinary tract infectionInfections and infestations4/855/833/310/400/40/400/421/400/10/100/10/400/20/11/421/413/410/53/280/51/410/6
Biliary obstructionHepatobiliary disorders0/850/830/310/400/40/400/421/400/11/100/10/400/20/10/420/410/410/50/280/50/410/6
CholangitisHepatobiliary disorders0/850/830/310/400/40/400/423/400/11/100/10/400/20/10/421/410/410/50/280/50/410/6
Cholangitis acuteHepatobiliary disorders0/850/830/310/400/40/400/420/400/11/100/10/400/20/10/420/410/410/50/280/50/410/6
Cholecystitis acuteHepatobiliary disorders0/850/830/310/400/40/400/421/400/11/100/10/400/20/10/422/410/410/50/280/50/410/6
Most frequent other events
Showing 10 of 191
Most frequent other events
EventCohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B1 Switch to PembrolizumabCohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D1 Switch to PembrolizumabCohort D2 MK-7684A + Gemcitabine + CisplatinCohort D2 Switch to Pembrolizumab + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort E to 2nd Course MK-7684A + 5-FU + CisplatinCohort E Switch to Pembrolizumab + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort H Switch to PembrolizumabCohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort I Switch to Pembrolizumab + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + OxaliplatinCohort J Switch to Pembrolizumab + Capecitabine + Oxaliplatin
Eye pruritusEye disorders0/850/830/310/400/40/400/420/400/10/101/10/400/20/10/420/410/410/50/280/50/410/6
Alanine aminotransferase increasedInvestigations12/8511/833/315/400/415/406/425/400/17/101/13/400/21/19/4213/414/410/56/281/520/410/6
Aspartate aminotransferase increasedInvestigations18/8511/834/315/400/414/405/426/400/14/100/13/400/21/17/4217/413/410/56/281/522/410/6
ArthralgiaMusculoskeletal and connective tissue disorders9/857/830/3110/400/44/404/421/400/14/101/14/400/20/16/428/417/410/54/281/53/410/6
DysuriaRenal and urinary disorders9/854/830/313/401/42/400/421/400/10/101/10/400/20/11/420/411/410/51/280/50/410/6
Rash maculo-papularSkin and subcutaneous tissue disorders8/855/831/319/400/46/402/422/400/14/101/12/400/20/17/424/415/410/54/280/54/410/6
AnaemiaBlood and lymphatic system disorders38/8535/8311/3113/401/48/409/4210/400/18/100/123/400/20/120/4212/4110/410/516/280/520/411/6
ConstipationGastrointestinal disorders17/8516/836/3110/400/44/406/423/400/16/100/18/400/20/18/425/414/410/56/280/56/410/6
NauseaGastrointestinal disorders17/8510/8312/3117/400/412/407/426/400/16/100/118/400/20/111/4217/411/410/510/280/514/410/6
FatigueGeneral disorders13/8515/835/3113/400/414/409/4213/400/16/100/117/400/20/19/4222/416/410/56/280/518/411/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + OxaliplatinTotal
Mean53.1 ± 11.749.4 ± 10.953.8 ± 13.163.2 ± 7.366.7 ± 7.661.9 ± 9.761.8 ± 12.258.6 ± 10.862.8 ± 10.551.8 ± 13.366.3 ± 11.874.4 ± 9.064.0 ± 13.062.5 ± 12.259.5 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + OxaliplatinTotal
Female858431414162385421493013432
Male00000371823502732028179
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + OxaliplatinTotal
Hispanic or Latino271861237765182112929180
Not Hispanic or Latino394418203123312332318291511337
Unknown or Not Reported1922797133221206194
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + OxaliplatinTotal
American Indian or Alaska Native100000000000001
Asian1414817151429151315109
Native Hawaiian or Other Pacific Islander000000000000000
Black or African American000100000000001
White544715312716246273732231632387
More than one race1624100133256337
Unknown or Not Reported1517646123111207176
Investigator Choice of Use of Bevacizumab
Investigator Choice of Use of Bevacizumab(Count of Participants)Cohort A1 MK-7684ACohort A1 PembrolizumabCohort A2 MK-7684ACohort B1 MK-7684ACohort B2 MK-7684A + Lenvatinib 20 mgCohort C MK-7684ACohort D1 MK-7684ACohort D2 MK-7684A + Gemcitabine + CisplatinCohort E MK-7684A + 5-FU + CisplatinCohort F MK-7684A + PaclitaxelCohort G MK-7684A + Lenvatinib 12 mg/ 8 mgCohort H MK-7684ACohort I MK-7684A + Carboplatin + Paclitaxel + BevacizumabCohort J MK-7684A + Capecitabine + OxaliplatinTotal
Yes4040————————————80
No4544————————————89
08

Study locations

73 sites
  • Alaska Womens Cancer Care ( Site 1016)
    Anchorage, Alaska 99508, United States
  • City of Hope Comprehensive Cancer Center ( Site 1001)
    Duarte, California 91010, United States
  • University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente
    Orange, California 92868-3201, United States
  • Karmanos Cancer Institute ( Site 1007)
    Detroit, Michigan 48201, United States
  • Memorial Sloan Kettering - Basking Ridge ( Site 1023)
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan Kettering - Monmouth ( Site 1022)
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering - Bergen ( Site 1025)
    Montvale, New Jersey 07645, United States
  • Memorial Sloan Kettering- Commack ( Site 1021)
    Commack, New York 11725, United States
  • Memorial Sloan Kettering - Westchester ( Site 1020)
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center ( Site 1002)
    New York, New York 10065, United States
  • Memorial Sloan Kettering - Nassau ( Site 1026)
    Uniondale, New York 11553, United States
  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)
    Tulsa, Oklahoma 74146, United States
  • Sanford Cancer Center-Gynecologic Oncology ( Site 1015)
    Sioux Falls, South Dakota 57104, United States
  • Houston Methodist Hospital ( Site 1017)
    Houston, Texas 77030, United States
  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)
    Kingston, Ontario K7L 2V7, Canada
  • Princess Margaret Cancer Centre ( Site 1056)
    Toronto, Ontario M5G 2M9, Canada
  • James Lind Centro de Investigacion del Cancer ( Site 1404)
    Temuco, Araucania 4800827, Chile
  • FALP-UIDO ( Site 1401)
    Santiago, Region M. de Santiago 7500921, Chile
  • Oncovida ( Site 1405)
    Santiago, Region M. de Santiago 7510032, Chile
  • Bradfordhill-Clinical Area ( Site 1402)
    Santiago, Region M. de Santiago 8420383, Chile
  • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)
    Medellín, Antioquia 050030, Colombia
  • Clinica de la Costa S.A.S. ( Site 1421)
    Barranquilla, Atlántico 080020, Colombia
  • Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)
    Bogotá, Cundinamarca 111511, Colombia
  • Oncologos del Occidente ( Site 1424)
    Pereira, Risaralda Department 661001, Colombia
  • Fundación Cardiovascular de Colombia ( Site 1423)
    Piedecuesta, Santander Department 681017, Colombia
  • CENTRE LEON BERARD-Medical oncology ( Site 1151)
    Lyon, Auvergne-Rhône-Alpes 69373 Cedex 08, France
  • Centre Georges François Leclerc ( Site 1155)
    Dijon, Cote-d Or 21079, France
  • Institut Regional du Cancer Montpellier ( Site 1157)
    Montpellier, Herault 34298, France
  • Gustave Roussy-medicine departement ( Site 1153)
    Villejuif, Paris 94800, France
  • Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)
    Avignon, Vaucluse 84000, France
  • Institut Curie ( Site 1152)
    Paris, 75248, France
  • Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Klinikum der Universität München Großhadern ( Site 1176)
    München, Bavaria 81337, Germany
  • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)
    Berlin, 12203, Germany
  • Rambam Health Care Campus-Oncology ( Site 1141)
    Haifa, 3109601, Israel
  • Hadassah Medical Center-Oncology ( Site 1142)
    Jerusalem, 9112001, Israel
  • Sheba Medical Center-ONCOLOGY ( Site 1144)
    Ramat Gan, 5265601, Israel
  • Sourasky Medical Center-Oncology ( Site 1143)
    Tel Aviv, 6423906, Israel
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136)
    Rome, Lazio 00168, Italy
  • Ospedale San Raffaele-Oncologia Medica ( Site 1135)
    Milan, Lombardy 20132, Italy
  • Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138)
    Rozzano, Milano 20089, Italy
  • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
    Milan, 20141, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134)
    Naples, 80131, Italy
  • Aichi Cancer Center Hospital ( Site 1324)
    Nagoya, Aichi-ken 464-8681, Japan
  • National Cancer Center Hospital East ( Site 1321)
    Kashiwa, Chiba 277-8577, Japan
  • Osaka International Cancer Institute ( Site 1323)
    Osaka, 541-8567, Japan
  • National Cancer Center Hospital ( Site 1322)
    Tokyo, 104-0045, Japan
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121)
    Amsterdam, North Holland 1066CX, Netherlands
  • Erasmus Medisch Centrum-Medical Oncology ( Site 1122)
    Rotterdam, South Holland 3015 GD, Netherlands
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
  • Seoul National University Hospital-Internal Medicine ( Site 1312)
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)
    Seoul, 03722, South Korea
  • Asan Medical Center ( Site 1313)
    Seoul, 05505, South Korea
  • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)
    Hospitalet, Barcelona 08907, Spain
  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)
    Pozuelo de Alarcón, Madrid 28223, Spain
  • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)
    Madrid, Madrid, Comunidad de 28034, Spain
  • Clinica Universidad de Navarra-Medical Oncology ( Site 1118)
    Madrid, 28027, Spain
  • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)
    Seville, 41013, Spain
  • NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)
    Tainan, 704, Taiwan
  • National Taiwan University Hospital-Oncology ( Site 1301)
    Taipei, 10002, Taiwan
  • Mackay Memorial Hospital ( Site 1305)
    Taipei, 10449, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch ( Site 1304)
    Taoyuan, 333, Taiwan
  • Istanbul Universitesi Cerrahpasa ( Site 1203)
    Istanbul- Fatih, Istanbul 34098, Turkey (Türkiye)
  • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201)
    Adana, 01250, Turkey (Türkiye)
  • Hacettepe Universitesi-oncology hospital ( Site 1209)
    Ankara, 06230, Turkey (Türkiye)
  • Ankara City Hospital-Medical Oncology ( Site 1202)
    Ankara, 06800, Turkey (Türkiye)
  • Trakya University-Medical Oncology ( Site 1207)
    Edirne, 22030, Turkey (Türkiye)
  • Acibadem Universitesi Atakent Hastanesi ( Site 1208)
    Istanbul, 34303, Turkey (Türkiye)
  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204)
    Istanbul, 34722, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Aug 2025, 46 months.

Results were first posted in Sep 2026, 1 year 1 month after primary completion.

Of 50 industry-sponsored phase 2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 46. This study's 46 months is above that.

Counting every sponsor, half of 205 studies reached it within 42 months; a quarter within 29 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2021
First posted
Aug 16, 2021
StartActual
Sep 16, 2021
Primary completionActual
Aug 5, 2025
CompletionActual
Aug 5, 2025
Results first posted
Sep 28, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 28, 2026
Enrollment
613→611
Sep 28, 2026
Primary outcomes
5 edited
What changed in the outcomes
  • EditedObjective Response Rate (ORR) perPer Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1Time frame: Up to approximately 2 years → Up to approximately 24 months
  • EditedProgression-Free Survival (PFS) perPer RECIST 1.1 as Assessed by BICR in Cohort A1Time frame: Up to approximately 2 years → Up to approximately 24 months
  • EditedORR perPer RECIST 1.1 as Assessed by Investigator in Participants withWith Selected Solid TumorsTime frame: Up to approximately 2 years → Up to approximately 24 months
  • EditedProgression Free Survival (PFS per) Per RECIST 1.1 as Assessed by Investigator at 9 monthsMonthsTime frame: 9 months
  • EditedPFS perPer RECIST 1.1 as Assessed by Investigator at 12 monthsMonthsTime frame: 12 months
Sep 28, 2026
Documents
Secondary outcomes
8 edited, 2 time frame changed, 2 description edited
What changed in the outcomes
  • EditedOverall Survival (OS) in Participants With Selected Solid TumorsTime frame: Up to approximately 5.5 years → Up to approximately 46 months
  • EditedPFS perPer RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid TumorsTime frame: Up to approximately 2 years → Up to approximately 46 months
  • EditedDuration of Response (DOR) perPer RECIST 1.1 as Assessed by BICR in Cohort A1Time frame: Up to approximately 2 years → Up to approximately 46 months
  • EditedDOR perPer RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid TumorsTime frame: Up to approximately 2 years → Up to approximately 46 months
  • EditedORR perPer RECIST 1.1 as Assessed by Investigator in Cohort A1Time frame: Up to approximately 2 years → Up to approximately 24 months
  • EditedPFS perPer RECIST 1.1 as Assessed by Investigator in Participants with Cervical Cancerin Cohort A1Time frame: Up to approximately 2 years → Up to approximately 24 months
  • EditedChange fromFrom Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1Time frame: Baseline and up to approximately 2 years → Baseline and up to Week 12
  • EditedChange fromFrom Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1Time frame: Baseline and up to approximately 2 years → Baseline and up to Week 12
  • Time frameNumber of Participants Who Experienced One or More Adverse Events (AEs)Up to approximately 2 years → Up to approximately 46 months
  • Time frameNumber of Participants Who Discontinued Study Intervention Due to an AEUp to approximately 2 years → Up to approximately 46 months
  • DescriptionNumber of Participants Who Discontinued Study Intervention Due to an AE: how it is measured was reworded
  • DescriptionNumber of Participants Who Experienced One or More Adverse Events (AEs): how it is measured was reworded
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Results posted
    Enrollment 613→611
    Primary outcomes 5 edited
    What changed in the outcomes
    • EditedObjective Response Rate (ORR) perPer Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1Time frame: Up to approximately 2 years → Up to approximately 24 months
    • EditedProgression-Free Survival (PFS) perPer RECIST 1.1 as Assessed by BICR in Cohort A1Time frame: Up to approximately 2 years → Up to approximately 24 months
    • EditedORR perPer RECIST 1.1 as Assessed by Investigator in Participants withWith Selected Solid TumorsTime frame: Up to approximately 2 years → Up to approximately 24 months
    • EditedProgression Free Survival (PFS per) Per RECIST 1.1 as Assessed by Investigator at 9 monthsMonthsTime frame: 9 months
    • EditedPFS perPer RECIST 1.1 as Assessed by Investigator at 12 monthsMonthsTime frame: 12 months
    Secondary outcomes 8 edited, 2 time frame changed, 2 description edited
    What changed in the outcomes
    • EditedOverall Survival (OS) in Participants With Selected Solid TumorsTime frame: Up to approximately 5.5 years → Up to approximately 46 months
    • EditedPFS perPer RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid TumorsTime frame: Up to approximately 2 years → Up to approximately 46 months
    • EditedDuration of Response (DOR) perPer RECIST 1.1 as Assessed by BICR in Cohort A1Time frame: Up to approximately 2 years → Up to approximately 46 months
    • EditedDOR perPer RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid TumorsTime frame: Up to approximately 2 years → Up to approximately 46 months
    • EditedORR perPer RECIST 1.1 as Assessed by Investigator in Cohort A1Time frame: Up to approximately 2 years → Up to approximately 24 months
    • EditedPFS perPer RECIST 1.1 as Assessed by Investigator in Participants with Cervical Cancerin Cohort A1Time frame: Up to approximately 2 years → Up to approximately 24 months
    • EditedChange fromFrom Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1Time frame: Baseline and up to approximately 2 years → Baseline and up to Week 12
    • EditedChange fromFrom Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1Time frame: Baseline and up to approximately 2 years → Baseline and up to Week 12
    • Time frameNumber of Participants Who Experienced One or More Adverse Events (AEs)Up to approximately 2 years → Up to approximately 46 months
    • Time frameNumber of Participants Who Discontinued Study Intervention Due to an AEUp to approximately 2 years → Up to approximately 46 months
    • DescriptionNumber of Participants Who Discontinued Study Intervention Due to an AE: how it is measured was reworded
    • DescriptionNumber of Participants Who Experienced One or More Adverse Events (AEs): how it is measured was reworded
    + 4 other changes: index terms, identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05007106
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Sep 16, 2021
Primary completion
Aug 5, 2025
Completion
Aug 5, 2025
Results posted
Sep 28, 2026
Last update
Sep 28, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vibostolimab/Pembrolizumab MK-7684A

Start the discussion